Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Comprehensive (Epi)Genetic Tumor Characterization and Disease Follow-Up in Multiple Myeloma Using Blood-Derived Cell-Free DNA

Robbe Heestermans, Catharina Olsen, Jana Succari, Shervine Ameli, Toon Janssen, Ann De Becker, Isabelle Vande Broek, Marleen Bakkus, Rik Schots, Elke De Bruyne, Ivan Van Riet

Blood (2024) 144 (Supplement 1): 3312.

https://doi.org/10.1182/blood-2024-209999

Published: 2024

Journal Articles

Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, Frédéric Baron, MD PhD, Chantal Lechanteur, Etienne Baudoux, Alexandra Briquet, Dominik Selleslag, MD, Johan A. Maertens, MD PhD, Xavier Poire, Wilfried Schroyens, MD PhD, Carlos Graux, Rik Schots, Pierre Zachée, Aurelie Ory, Julie Herman, Tessa Kerre, Yves Beguin, MD PhD

Blood (2019) 134 (Supplement_1): 37.

https://doi.org/10.1182/blood-2019-129992

Published: 2019

Journal Articles

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Inge Oudaert, MSc, Sylvia Faict, MSc, Ludovic D'Auria, PhD, Jonas Dehairs, PhD, Ken Maes, Philip Vlummens, MD, Lotte Jacobs, BSc, Kim De Veirman, Elke De Bruyne, PhD, Karel Fostier, MD, Isabelle Vande Broek, MD PhD, Rik Schots, Karin Vanderkerken, PhD, Johannes V. Swinnen, PhD, Eline Menu, PhD

Blood (2019) 134 (Supplement_1): 3058.

https://doi.org/10.1182/blood-2019-122857

Published: 2019

Journal Articles

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Sylvia Faict, MD, Josephine Muller, PhD, Kim De Veirman, PhD, Ken Maes, Elke De Bruyne, PhD, Rik Schots, Jo Caers, MD PhD, Karin Vanderkerken, PhD, Eline Menu, PhD

Blood (2018) 132 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2018-99-112428

Published: 2018

Journal Articles

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Jordi Esteve, MD PhD, Rik Schots, Teresa Bernal Del Castillo, MD PhD, Je-Hwan Lee, MD PhD, Eunice S. Wang, MD, Shira Dinner, MD, Mark D. Minden, MD PhD, Olga Salamero, MD, Jorge Sierra, MD, Goichi Yoshimoto, MD PhD, Kamel Laribi, MD, Janusz Halka, MD, Pau Montesinos, MD PhD, Shufang Liu, Elizabeth Shima Rich, MD PhD, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 2736.

https://doi.org/10.1182/blood-2018-99-110976

Published: 2018

Journal Articles

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Timothy Devos, Koen Theunissen, Fleur Samantha Benghiat, Alain Gadisseur, Stef Meers, Dominik Selleslag, Gaëtan Vanstraelen, Pierre Zachée, Marc André, Philippe Lewalle, MD, Mia Janssen, Rik Schots, Koen Van Eygen, Alain Kentos, Marie Lejeune, Agnes Triffet, Inge Vrelust, Carolina Kuipers, Violaine Havelange

Blood (2018) 132 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2018-99-114070

Published: 2018

Journal Articles

Long-Term Survival and Quality of Life Analysis after Autologous Stem Cell Transplantation for Lymphoma

Sylvia Faict, MD, Nathan De Beule, MD, Ann De Becker, MD, Karel Fostier, MD, Fabienne Trullemans, MD, Henri (Rik) Schots, MD PhD

Blood (2016) 128 (22): 2268.

https://doi.org/10.1182/blood.V128.22.2268.2268

Published: 2016

Journal Articles

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

Blood (2015) 126 (23): 730.

https://doi.org/10.1182/blood.V126.23.730.730

Published: 2015

Journal Articles

Long-Term Safety Follow-up of a Randomized Trial of Darbepoetin Alpha and Intravenous Iron Following Autologous Hematopoietic Cell Transplantation

Aurélie Jaspers, MD, Frederic Baron, MD PhD, Johan Maertens, MD PhD, Bernard J. M. De Prijck, MD, Henri (Rik) Schots, MDPhD, Christophe Bonnet, MD PhD, Kaoutar Hafraoui, MD, Evelyne Willems, MD PhD, Sophie Servais, MD PhD, Georges Fillet, MD PhD, Yves Beguin, MD PhD

Blood (2014) 124 (21): 3948.

https://doi.org/10.1182/blood.V124.21.3948.3948

Published: 2014

Journal Articles

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results

Blood (2014) 124 (21): 2112.

https://doi.org/10.1182/blood.V124.21.2112.2112

Published: 2014

Journal Articles

Immunomodulatory Drugs Restore Effector Cell Immune Functions In Myeloma Patients With Low Disease Burden After Autologous Stem Cell Transplantation

Karel Fostier, MD, Jurgen Corthals, Carlo Heirman, Joeri L. Aerts, PhD, Kris Thielemans, MD, PhD, Rik Schots, MD, PhD, Brenda De Keersmaecker, PhD

Blood (2013) 122 (21): 3214.

https://doi.org/10.1182/blood.V122.21.3214.3214

Published: 2013

Journal Articles

Outcomes Of Allogeneic Cord Blood Transplantation For Leukodystrophies; A Joint Study of Eurocord and “Inborn Errors WP-EBMT”

Blood (2013) 122 (21): 2101.

https://doi.org/10.1182/blood.V122.21.2101.2101

Published: 2013

Journal Articles

Dll1/Notch Interaction Contributes to a Decreased Sensitivity of Myeloma Cells to Bortezomib

Dehui Xu, Jingsong Hu, Elke De Bruyne, PhD, Eline Menu, PhD, Rik Schots, MD, Karin Vanderkerken, PhD, Els Van Valckenborgh, PhD

Blood (2012) 120 (21): 1840.

https://doi.org/10.1182/blood.V120.21.1840.1840

Published: 2012

Journal Articles

Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant

Ruth Pettengell, MD, Norbert Schmitz, MD, Christian Gisselbrecht, MD, Graeme Smith, MD, William N Patton, MD, Bernd Metzner, MD, Dolores Caballero, MD, Herve Tilly, MD, Jan A Walewski, MD, Isabelle Bence-Bruckler, MD, Bik To, MD, Christian H. Geisler, MD, Rik Schots, MD, Eva Kimby, MD, Christian J. Taverna, MD, T. Kozak, MD, Ruzena Uddin, MSci, Carmen Ruiz de Elvira, PhD, Anthony H. Goldstone, MD

Blood (2010) 116 (21): 3567.

https://doi.org/10.1182/blood.V116.21.3567.3567

Published: 2010

Journal Articles

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

Blood (2009) 114 (22): 3859.

https://doi.org/10.1182/blood.V114.22.3859.3859

Published: 2009

Journal Articles

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

Jean-Luc Harousseau, Antonio Palumbo, Paul Richardson, Rudolf Schlag, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Rik Schots, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F San Miguel

Blood (2008) 112 (11): 2778.

https://doi.org/10.1182/blood.V112.11.2778.2778

Published: 2008

Journal Articles

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

Meletios A Dimopoulos, Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin H Kropff, Maria Teresa Petrucci, Michel Delforge, Julia A Alexeeva, Rik Schots, Tamas Masszi, Maria-Victoria Mateos, William Deraedt, Kevin Liu, Andrew Cakana, Helgi van de Velde, Jesus F San Miguel

Blood (2008) 112 (11): 1727.

https://doi.org/10.1182/blood.V112.11.1727.1727

Published: 2008

Journal Articles

Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial

Yves Beguin, Johan Maertens, Bernard De Prijck, Rik Schots, MD, Pascale Frere, Christophe Bonnet, Kaoutar Hafraoui, Evelyne Willems, Gaetan Vanstraelen, Marie Lejeune, Koen Theunissen, Georges Fillet, Frederic Baron

Blood (2008) 112 (11): 54.

https://doi.org/10.1182/blood.V112.11.54.54

Published: 2008

Journal Articles

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Blood (2008) 112 (11): 650.

https://doi.org/10.1182/blood.V112.11.650.650

Published: 2008

Journal Articles

Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial

Thierry Facon, Jean-Luc Harousseau, Frédéric Maloisel, Michel Attal, Jesus Odriozola, Adrian Alegre, Wilfried Schroyens, Cyrille Hulin, Rik Schots, Pedro Marin, François Guilhot, Albert Granena, Marc De Waele, Arnaud Pigneux, Valérie Méresse, Peter Clark, Josy Reiffers, the SCF-Multiple Myeloma Study Group

Blood (1999) 94 (4): 1218–1225.

https://doi.org/10.1182/blood.V94.4.1218

Published: 1999

NARROW

Comprehensive (Epi)Genetic Tumor Characterization and Disease Follow-Up in Multiple Myeloma Using Blood-Derived Cell-Free DNA

Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Long-Term Survival and Quality of Life Analysis after Autologous Stem Cell Transplantation for Lymphoma

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

Long-Term Safety Follow-up of a Randomized Trial of Darbepoetin Alpha and Intravenous Iron Following Autologous Hematopoietic Cell Transplantation

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results

Immunomodulatory Drugs Restore Effector Cell Immune Functions In Myeloma Patients With Low Disease Burden After Autologous Stem Cell Transplantation

Outcomes Of Allogeneic Cord Blood Transplantation For Leukodystrophies; A Joint Study of Eurocord and “Inborn Errors WP-EBMT”

Dll1/Notch Interaction Contributes to a Decreased Sensitivity of Myeloma Cells to Bortezomib

Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only